Indian Immunologicals Limited (IIL) has set up its second manufacturing facility at Karkapatla, Ranga Reddy district, Telangana with an investment of ?250 crore.



The unit at Phase III of Genome Valleywill expand IIL's manufacturing capabilities. It will make vaccines against infectious diseases of humans & animal health formulations. The first phase of human vaccine facility has the capacity to produce 8 million doses of human rabies vaccine.



The animal health formulation facility is equipped to produce 300 million tablets, 100 million bolus (animal vaccine), and 20 million vials of injectables, said K Anand Kumar, Deputy Managing Director, IIL, the fully-owned subsidiary of NDDB.



HBL

here is company details.

 

NOTE :You need to login first to access this feature.